surmount-1 trial tirzepatide non-diabetic weight loss (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants Tirzepatide Delivers in SURMOUNT-2 -

If you're interested in learning more about how Mounjaro (Tirzepatide) works for weight loss and whether or not it's right for you, talk with your doctor today

People maintaining treatment continue experiencing appetite suppression and weight loss maintenance as long as they continue the medication

"That 37% is an average regain of the weight lost, so that's also an optimistic way to look at it, because that means you've retained about 63% of your weight loss." How much weight someone will regain after stopping weight-loss medications and the speed at which it comes back will vary from individual to individual

Nausea appears or intensifies

Some patients prefer evening injections, reasoning that sleeping through the initial hours post-injection may reduce awareness of nausea

For patients paying out of pocket for weight loss treatment, Zepbound vials are significantly more affordable than Mounjaro at retail pricing, making Zepbound the better choice for cash-paying patients seeking tirzepatide